


Zoledronic acid every 12 weeks noninferior in bone metastases

January 4 2017



(HealthDay)—Use of zoledronic acid every 12 weeks does not result in

increased risk of skeletal events compared with use every four weeks among patients with bone metastases due to breast cancer, prostate cancer, or multiple myeloma, according to a study published in the Jan. 3 issue of the *Journal of the American Medical Association*.

Andrew L. Himmelstein, M.D., from the Helen F. Graham Cancer Center & Research Institute in Newark, Del., and colleagues randomized 1,822 patients with metastatic [breast cancer](#), metastatic [prostate cancer](#), or [multiple myeloma](#) with at least one site of bone involvement to receive zoledronic acid administered intravenously every four weeks or every 12 weeks (911 each) for two years. Of the patients, 795 completed the study at two years.

The researchers found that 29.5 and 28.6 percent of patients in the zoledronic acid four-week and 12-week groups, respectively, experienced at least one skeletal-related event within two years of randomization (risk difference, -0.3 percent; P zoledronic acid every 12 weeks).

"This longer interval may be an acceptable treatment option," the authors write.

Two authors disclosed financial ties to the pharmaceutical industry.

More information: [Full Text \(subscription or payment may be required\)](#)

Copyright © 2017 [HealthDay](#). All rights reserved.

Citation: Zoledronic acid every 12 weeks noninferior in bone metastases (2017, January 4) retrieved 11 May 2024 from <https://medicalxpress.com/news/2017-01-zoledronic-acid-weeks-noninferior-bone.html>

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.